WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Â Proceeds will be used...
1k Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
987 Views
WuXi Biologics: Updated Valuation Data
We have heard that WuXi Biologics' bankers are preparing to move forward with the offering though a PHIP has not been posted yet. Â The updated...
885 Views
An Intriguing Small Cap with Price Risk
SummaryGenscript Biotech (1548 HK) is a pending small cap healthcare IPO. Â We think Genscript is a very interesting company because of its leading...
426 Views